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Forkhead box-containing protein o (Foxo) 1 is a key
transcription factor in insulin and glucose metabolism.
We identiﬁed a Foxo1-CoRepressor (FCoR) protein in
mouse adipose tissue that inhibits Foxo1’s activity by
enhancing acetylation via impairment of the interaction
between Foxo1 and the deacetylase Sirt1 and via direct
acetylation. FCoR is phosphorylated at Threonine 93 by
catalytic subunit of protein kinase A and is translocated
into nucleus, making it possible to bind to Foxo1 in both
cytosol and nucleus. Knockdown of FCoR in 3T3-F442A
cells enhanced expression of Foxo target and inhibited
adipocyte differentiation. Overexpression of FCoR in white
adipose tissue decreased expression of Foxo-target genes
and adipocyte size and increased insulin sensitivity in
Lepr
db/db mice and in mice fed a high-fat diet. In contrast,
Fcor knockout mice were lean, glucose intolerant, and had
decreased insulin sensitivity that was accompanied by
increased expression levels of Foxo-target genes and
enlarged adipocytes. Taken together, these data suggest
that FCoR is a novel repressor that regulates insulin
sensitivity and energy metabolism in adipose tissue by
acting to ﬁne-tune Foxo1 activity.
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Introduction
Forkhead transcription factor (Foxo1) is a key transcription
factor in insulin and glucose metabolism that is phosphory-
lated, subsequently exported to the cytoplasm, and inhibited
by insulin/IGF1 in a PI3 kinase-dependent manner (Accili
and Arden, 2004). Foxo1 plays an important role in mediating
insulin action in several insulin-responsive tissues.
Speciﬁcally, Foxo1 promotes glucose production in the liver,
inhibits compensatory b-cell proliferation in insulin-resistant
states, activates feeding by promoting orexigenic peptide
expression in the hypothalamic arcuate nucleus, inhibits
differentiation of preadipocytes and myoblasts into mature
adipocytes or myotubes, and regulates energy storage and
expenditure in adipose tissue (Nakae et al, 2008a, b). Because
of its involvement in so many physiological processes, it is
important to elucidate the mechanism that regulates Foxo1
transcriptional activity.
Adipogenesis, during which preadipocytes differentiate
into adipocytes, experiences several stages, including me-
senchymal precursor, committed preadipocytes, growth-ar-
rested preadipocyte, mitotic clonal expansion, terminal
differentiation, and mature adipocyte (Lefterova and Lazar,
2009). Peroxisome proliferator-activated receptor-g (PPARg)
regulates both the terminal differentiation and metabolism in
mature adipocytes. Foxo1 is a PPARg-interacting protein that
antagonizes PPARg activity (Dowell et al, 2003; Armoni et al,
2006; Fan et al, 2009). SirT2-mediated deacetylation of Foxo1
increases the association of Foxo1 with PPARg, leading to
inhibition of adipocyte differentiation (Jing et al, 2007).
Furthermore, constitutively nuclear (CN) Foxo1 inhibits
differentiation of the preadipocyte cell line 3T3-F442A cells
by arresting the cell cycle that is required in the early stages
of adipose conversion, whereas haploinsufﬁciency of Foxo1
restores the size of white adipocytes under high-fat diet
(HFD) (Nakae et al, 2003; Kim et al, 2009). Overexpression
of transactivation-defective Foxo1 in white adipose tissue
(WAT) increases fat mass and number of small adipocytes.
Overexpression of the same mutant Foxo1 in brown adipose
tissue (BAT) increases oxygen consumption (Nakae et al,
2008a). Therefore, Foxo1 can be an attractive target to
improve the energy homeostasis in adipose tissue. Targeting
Foxo1 can increase energy store in WAT and increase energy
expenditure in BAT.
Foxo1 is primarily regulated by post-translational modiﬁ-
cations. In addition to Akt-induced phosphorylation, Foxo1 is
acetylated by histone acetyltransferases (HATs) such as
CREB-binding protein (CBP)/P300; Foxo1 deacetylation is
mediated by class I–III deacetylases, including the nicotin
amide adenine dinucleotide (NAD)-dependent histone deace-
tylase (HDAC), Sirt1 (Accili and Arden, 2004). Interaction
with other proteins also regulates the transcriptional activity
of Foxo family proteins (Foxos). For example, PPAR-g co-
activator 1a (PGC-1a) interacts with Foxo1 and stimulates
gluconeogenesis in the liver (Puigserver et al, 2003). SMK-1
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orthologue in C. elegans (Wolff et al, 2006), and the
Drosophila Melted gene product interacts with both Tsc1
and FOXO to inhibit FOXO activity (Teleman et al, 2005).
In the present study, we identiﬁed a novel Foxo1-binding
protein termed as Foxo1 CoRepressor (FCoR) in adipose
tissue using a yeast two-hybrid screen of a mouse 3T3-L1
cDNA library. We demonstrated that FCoR inhibits Foxo1
transcriptional activity through increased Foxo1 acetylation,
which is accompanied by preventing Foxo1 interaction with
the deacetylase Sirt1 and by direct acetylation. Knockdown of
FCoR in 3T3-F442A cells inhibited adipocyte differentiation,
while knockout of Fcor led to a lean phenotype, glucose
intolerance, and insulin resistance. In contrast, overexpres-
sion of FCoR in adipose tissue decreased adipocyte size,
increased insulin sensitivity, and decreased PGC-1a expres-
sion in brown adipocytes, indicating that FCoR plays impor-
tant roles in glucose and energy homeostasis.
Results
Identiﬁcation of FCoR, a novel Foxo1-binding protein
To identify Foxo1-interacting proteins, we performed a yeast
two-hybrid screen, using a GAL4-Foxo1 fragment (amino
acids 1–154) as bait and a mouse 3T3-L1 cDNA library as
prey. Screening of about 1.5 10
6 primary transformants
yielded 224 clones. We selected 17 clones that met the
following criteria: (1) they possessed a nuclear localization
signal, (2) they encoded transcription factors, or (3) un-
known proteins, and (4) they were restricted to or enriched
in adipose tissue and/or differentiated 3T3-F442A cells. In all,
5 of 17 clones thus identiﬁed encoded partial transcripts of
the RIKEN cDNA 2400009B08. The gene is predicted to
encode a peptide with an Mr of 13.71kDa LOC68234
(gb|EDL21945.1|mCG1048501). Because further characteriza-
tion showed that it acted as a Foxo1 CoRepressor, it was
termed as ‘FCoR’.
We performed 50-o r3 0-rapid ampliﬁcation of cDNA ends
(RACE) to determine the transcription start site
(Supplementary Figure S1A). Sequencing of the 50- and 30-
RACE products determined that FCoR is a 106-amino acid
protein (Supplementary Figure S1B). cDNA cloning and
in-vitro translation studies conﬁrmed that the peptide has a
molecular weight of 13kDa (Figure 1A). Functional domain
analysis using the Eukaryotic Linear Motif server (http://
elm.eu.org/; Teleman et al, 2005) revealed the presence of a
forkhead-associated ligand domain (LIG_FHA_1) from amino
acids 78 to 84 (Supplementary Figure S1B).
To conﬁrm the interaction between Foxo1 and FCoR, we
co-transfected HEK293 cells with FLAG-tagged Foxo1 and
cMyc-tagged FCoR and performed reciprocal immunoprecipi-
tation/immunoblotting experiments in the presence of serum
using anti-FLAG and anti-cMyc antibodies. These experi-
ments showed that FCoR interacted with Foxo1 (Figure 1B,
lanes 1–4). To identify the FCoR-binding site of Foxo1, we
co-transfected pFLAG-CMV2-D256 Foxo1, which encoded a
Foxo1 mutant lacking the carboxyl terminal transactivation
domain (Nakae et al, 2000), and pCMV5-cMyc-FCoR and
performed immunoprecipitation studies. These experiments
demonstrated that FLAG-D256 Foxo1 bound to cMyc-FCoR
(Figure 1B, lanes 5–8), suggesting that FCoR binds the Foxo1
N-terminus.
Foxo family members, including Foxo1, Foxo3a, and
Foxo4, are expressed in WAT and/or BAT. Foxo1 and Foxo3a
can be expressed in both WAT and BAT but Foxo4 is mainly
expressed in BAT (Supplementary Figure S2). To investigate
whether endogenous Foxo1 associates with FCoR, mouse
WAT and BAT extracts were immunoprecipitated with an
anti-FOXO1 antibody or anti-FCoR antiserum, followed by
immunoblotting with antibodies against FCoR or Foxo1. The
results showed that endogenous Foxo1 associated with
endogenous FCoR (Figure 1C). Taken together, these results
suggest that FCoR interacts with Foxo1 in vivo. To determine
whether the interaction between FCoR and Foxo1 was a direct
Figure 1 Interaction between FCoR and Foxos and expression proﬁling of FCoR. (A) In-vitro translation of FCoR. Lysates from liver (lane 1),
WAT (lane 2), and BAT (lane 3) from wild-type mice, along with in vitro-translated FCoR were analysed by western blotting using anti-mouse
FCoR antiserum. (B) Interaction between exogenous FCoR and Foxo1. HEK293 cells were co-transfected with pFLAG-CMV2-WT Foxo1 or
pFLAG-CMV2-D256 Foxo1 plus pCMV5-cMyc-WT FCoR and cultured in the presence of serum. At 48h after transfection, cells were harvested
and lysates were immunoprecipitated with anti-cMyc (lanes 1 and 5), anti-FLAG antibody (lanes 3 and 7), or normal mouse IgG (lanes 2, 4, 6,
and 8) and blotted with anti-FLAG (lanes 1, 2, 5, and 6) or anti-cMyc antibody (lanes 3, 4, 7, and 8). (C) Interaction between endogenous Foxo1
and FCoR in WATand BAT. Lysates from WAT (lanes 1, 2, 5, and 6) and BAT (lanes 3, 4, 7, and 8) were immunoprecipitated with anti-FOXO1
(lanes 1 and 3), anti-FCoR (lanes 5 and 6), or normal rabbit IgG (lanes 2, 4, 6, and 8) and blotted with anti-FCoR (lanes 1–4) or anti-FOXO1
(lanes 5–8), respectively. (D) Direct interaction of FCoR with Foxo1. GST-FCoR was subjected to a pull-down assay. Aliquots of in vitro-
translated WT Foxo1 were incubated with glutathione-Sepharose beads coated with bacterially expressed GST-P13 (lane 2) or GSTalone (lane
3) for 6h at 41C. The in vitro-translated Foxo1 proteins retained on the column were eluted and separated by SDS–PAGE followed by western
blotting with anti-FOXO1 antibody. The bottom panel shows GST or GST-GST-P13 (10% of input, lane 3) blotted with anti-GST antibody.
(E) Expression proﬁling of Fcor in various tissues. Total RNA isolated from WAT (lane 1), BAT (lane 2), liver (lane 3), skeletal muscle (lane 4),
and whole brain (lane 5) of wild-type mice was subjected to northern blotting with Fcor (top panel) or b-actin (bottom panel). (F) Real-time
PCR of Fcor using the adipocyte or stromal vascular fractions of fractionated WAT. (G) Northern blotting of 3T3-F442A cells during
differentiation. Total RNA isolated from 3T3-F442A cells on the indicated day after induction of differentiation was subjected to Northern
blotting with Fcor (top panel) or b-actin (bottom panel). (H) Western blotting of FCoR protein from 3T3-F442A cells during differentiation.
Lysates from 3T3-F442A cells on the indicated day after induction of differentiation were subjected to western blotting using anti-FCoR
polyclonal antiserum (top panel) or anti-tubulin monoclonal antibody (bottom panel). (I) Effects of the feeding state on Fcor gene expression.
Total RNA from liver (lanes 1–3), WAT (lanes 4–6), and BAT (lanes 7–9) from C57Bl6J mice in the fed, fasting, or refed states was subjected to
northern blotting with Fcor (top panel) or b-actin (bottom panel). (J) Western blotting of the FCoR protein from WAT (lanes 1 and 2) and BAT
(lanes 3 and 4) from C57Bl6J mice in fed (lanes 1 and 3) or fasting state (lanes 2 and 4). Tissue lysates were subjected to western blotting using
anti-FCoR polyclonal antiserum (top panel) or anti-tubulin monoclonal antibody (bottom panel). (K) Fcor gene expression in WAT and BAT
from Lepr
db/db mice. Total RNA isolated from WAT (lanes1 and 2) and BAT (lanes 3 and 4) of C57Bl6J (lanes 1 and 3) or Lepr
db/db mice (lanes 2
and 4) was subjected to northern blotting with Fcor (top panel) or b-actin (bottom panel). (L) Effect of cold exposure on Fcor gene expression in
BAT. Total RNA isolated from the BATof C57Bl6J mice exposed to the cold (41C for 6h) was subjected to northern blotting with Fcor (top panel)
or b-actin (bottom panel). (M) Immunohistochemistry of WAT (left panel) and BAT (right panel) from C57Bl6J mice using anti-FCoR anti-sera.
Scale bars indicate 20mm.
A novel repressor of Foxo1
J Nakae et al
2276 The EMBO Journal VOL 31 | NO 10 | 2012 &2012 European Molecular Biology Organizationinteraction, we performed a GST-fusion protein pull-down
assay. We detected an interaction between FCoR and Foxo1
(Figure 1D), indicating that the two proteins bind directly to
one another.
FCoR is expressed in adipose tissue and differentiated
3T3-F442A cells
Fcor mRNA is expressed in mouse WAT and BAT, but not in
liver, skeletal muscle, or brain (Figure 1E). Fractionation
of WAT revealed that Fcor is expressed mainly in the
adipocyte fraction (Figure 1F). Analysis of Fcor mRNA and
protein levels indicated that FCoR is expressed in
3T3-F442A cells in a differentiation-dependent manner
(Figure 1G and H).
To investigate whether FCoR expression was modulated in
physiological conditions or insulin-resistant states, we exam-
ined Fcor mRNA regulation during fasting and feeding in
C57bl6J mice. Fcor mRNA and FCoR protein levels in WAT
and BAT decreased during fasting (Figure 1I and J), and Fcor
mRNA expression levels were lower in the WAT and BAT of
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db/db mice compared with control mice
(Figure 1K). BAT is the main organ responsible for adaptive
thermogenesis in rodents (Cannon et al, 1998). Interestingly,
mouse BAT Fcor mRNA expression increased after 6h of cold
exposure (Figure 1L). Immunohistochemistry experiments
demonstrated that the endogenous FCoR protein was ex-
pressed mainly in the nucleus in both WAT and BAT
(Figure 1M). These data suggest that FCoR may have a
functional role in adipose tissues in vivo.
FCoR inhibits the transcriptional activity of Foxo1 and
Foxo3a, but not of FOXO4
We next addressed the question of whether FCoR affects
Foxo1 transcriptional activity using reporter assays with the
Foxo1-target genes Igfbp1 and G6pc (Nakae et al, 2006). A
constitutively nuclear Foxo1 mutant (CN Foxo1) increased
IGFBP1 or G6PC promoter activity by 3.5- and 22.5-fold,
respectively, in the presence of 8-Br-cAMP/IBMX/
dexamethasone (Figure 2A and B). FCoR had no effect on
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inhibited the Foxo1-dependent promoter activity of both
genes in a dose-dependent manner (Figure 2A and B). In
the transactivation assay, FCoR repressed the forskolin-in-
duced luciferase activity of a GAL4-Foxo1 fusion protein
(Figure 2C). Furthermore, co-expression of FCoR inhibited
the effect of CN Foxo1 on the expression of the endogenous
Igfbp1 gene in SV40-transformed hepatocytes (Figure 2D). In
these cells, FCoR localized to both the cytosol and nucleus
(Supplementary Figure S3). These data indicate that FCoR
and CN Foxo1 colocalize in the nucleus and that FCoR
inhibits Foxo-dependent transcription.
We also investigated whether other Foxo proteins (Foxo3a
and Foxo4) co-immunoprecipitated with FCoR in the absence
of serum and in the presence of forskolin. Transfection
studies indicated that epitope-tagged Foxo3a also interacted
with FCoR, but Foxo4 did not (Figure 2E). Furthermore, the
transactivation assay demonstrated that FCoR repressed the
forskolin-induced luciferase activity of a GAL4-Foxo1 fusion
protein and a GAL4-Foxo3a fusion protein but did not repress
the luciferase activity of a GAL4-FOXO4 fusion protein
(Figure 2F). These data suggest that of the Foxo family
members, FCoR interacts with Foxo1 and Foxo3a.
FCoR enhances the acetylation of Foxo1 through
disruption of the interaction between Foxo1 and Sirt1
and through direct acetylation
Foxo is acetylated by CBP/P300 and deacetylated by Sirt1 or
Sirt2 (Accili and Arden, 2004; Jing et al, 2007). We examined
Foxo1 acetylation in HEK293 cells in the presence or absence
of FCoR. Foxo1 was acetylated in the presence of H2O2
(Figure 3A, lane 1) and overexpression of FCoR enhanced
Foxo1 acetylation (Figure 3A, lane 2). Sirt1 binds to acety-
lated Foxo1 (Brunet et al, 2004; Kitamura et al, 2005).
Accordingly, Sirt1 bound to Foxo1 in the presence of H2O2
(Figure 3B, lane 1). However, co-transfection with FCoR
decreased the amount of Sirt1 recovered in Foxo1 immuno-
precipitates (Figure 3B, lane 2). These data suggest that FCoR
disrupts the interaction between Foxo1 and Sirt1.
Furthermore, we performed 5XGAL4-luciferase assays using
‘constitutively acetylated’ (6KQ) and ‘acetylation-defective’
(6KR) mutant Foxo1 (Kitamura et al, 2005). WT Foxo1
increased luciferase activity by B18-fold, while FCoR
decreased WT Foxo1-induced luciferase activity by 40%
(Figure 3C). However, FCoR failed to affect reporter activity
induced by 6KQ or 6KR mutant Foxo1 (Figure 3C). These data
suggest that acetylation is required for FCoR inhibition of
Foxo1 transcriptional activity.
Interestingly, the amino-acid sequence of the carboxyl
terminus of FCoR (amino acids 73–86) shows high sequence
similarity to yeast Esa1 and other MYST members, including
yeast Sas3, Drosophila MOF, human TIP60, and human P/
CAF, which possess intrinsic HAT activity (Figure 3D). To
investigate whether FCoR has intrinsic acetyltransferase ac-
tivity, we performed an in-vitro acetylation assay using a GST-
FCoR fusion protein and truncated Foxo1 (amino acids
251–409) as a substrate. This truncated Foxo1 includes four
lysine residues that are acetylation sites (K259, K262, K271,
and K291) (Daitoku et al, 2003; Kitamura et al, 2005; Qiang
et al 2010). The in-vitro acetylation assay revealed that GST-
FCoR acetylated truncated Foxo1 (Figure 3E). However, the
relative activity of acetyltransferase of FCoR was B10% of
recombinant p300 (Figure 3F and G). To conﬁrm the impor-
tance and speciﬁcity of amino acid residues 78–87 for FCoR
activity, we performed site-directed mutagenesis of FCoR
(I78A, T80A, L81A, L85A, and L87A) and conducted
5XGAL4-luciferase assays. Although wild-type FCoR signiﬁ-
cantly suppressed Foxo1-induced luciferase activity, most
mutations, except L81A, abolished the inhibition of Foxo1
(Figure 3H). Furthermore, this region, amino acids 78–87,
corresponds to an LIG_FHA_1. These data suggest that FCoR
can acetylate Foxo1 directly and that amino acids 78–87 are
important for inhibition of Foxo1.
Phosphorylation of FCoR Threonine 93 regulates its
subcellular localization
To investigate the mechanism by which FCoR inhibits the
transcriptional activity of Foxo1, we next investigated the
subcellular localization of FCoR. In HEK293 cells, FCoR
localized mainly to the cytosol or mitochondria in the ab-
sence of forskolin (Figure 4A, and data not shown). However,
forskolin induced FCoR nuclear localization (Figure 4A) in a
Figure 2 FCoR inhibits Foxo1 transcriptional activity. FCoR inhibits CN Foxo1-induced IGFBP1 (A) and G6PC (B) promoter activity. After
transient transfection with IGFBP1/luciferase (p925GL3) (A) or a G6Pase/luciferase reporter vector (PicaGene/human G6Pase promoter-
luciferase) (B), SV40-transformed hepatocytes were infected with the indicated adenovirus. phRL-SV40 was used as an internal control for
transfection efﬁciency. After overnight serum deprivation and induction with dexamethasone/8-Br-cAMP/IBMX, cells were harvested and
luciferase activity was measured. Single and double asterisks indicate statistically signiﬁcant difference between luciferase activity in the
absence and the presence of FCoR (*Po0.005 and **Po0.05, respectively, by one-way ANOVA). Data represent the mean±s.e.m. from three
independent experiments. (C) FCoR inhibits Foxo1-induced 5XGAL4-luciferase activity. After transient transfection, HEK293 cells were
stimulated with forskolin (20mM) for 6h, harvested, and luciferase activity was measured. An asterisk indicates a statistically signiﬁcant
difference between luciferase activity in the absence and presence of FCoR (*Po0.02 by one-way ANOVA). Data represent the mean±s.e.m.
from three independent experiments. (D) Effect of overexpression of FCoR on endogenous Igfbp1 gene expression. SV40-transformed
hepatocytes were transduced with adenovirus encoding FLAG-CN Foxo1. After 2h, cells were transduced again with adenovirus encoding
cMyc-FCoR. After 36h, cells were incubated with dexamethasone/cAMP/IBMX for 8h and harvested. Total RNA was isolated from cells and
subjected to real-time PCR to analyse the Igfbp1 and b-actin levels. Data were corrected using the b-actin expression level and then represented
as relative mRNA abundance. Data represent the mean values±s.e.m. from three independent experiments. An asterisk indicates a statistically
signiﬁcant difference between endogenous Igfbp1 expression induced by FLAG-CN Foxo1 in the absence and presence of cMyc-FCoR
(*Po0.001 by one-way ANOVA). (E) Interaction between Foxo1, Foxo3a or FOXO4 and FCoR. HEK293 cells were co-transfected with pCMV5-
cMyc-Foxo1, pCMV5-cMyc-Foxo3a or pCMV5/cMyc-FOXO4 and pFLAG-CMV2-WT FCoR and immunoprecipitated with anti-FLAG, anti-cMyc
or normal mouse IgG and blotted with anti-cMyc or anti-FLAG antibody. (F) FCoR inhibits Foxo1-induced and Foxo3a-induced, but not FOXO4-
induced 5XGAL4-luciferase activity. After transient transfection with FCoR, HEK293 cells were stimulated with forskolin (20mM) for 6h,
harvested, and luciferase activity was measured. The grey bar indicates mock-transfected cells and the blue bar indicates pCMV5-cMyc-WT
FCoR-transfected cells. An asterisk indicates a statistically signiﬁcant difference between luciferase activity in the absence and presence of
FCoR (*Po0.01 by one-way ANOVA). Data represent the mean±s.e.m. from three independent experiments. Figure source data can be found
with the Supplementary data.
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These data suggest that forskolin promotes FCoR nuclear
localization in HEK293 cells. Furthermore, we investigated
subcellular localization of endogenous FCoR in 3T3-F442A
cells during differentiation. At 48h after induction, in the
presence of 3-isobutyl-1-methylxanthine (IBMX), which is a
competitive non-selective phosphodiesterase inhibitor and
raises intracellular cAMP and activates PKA, FCoR was
localized in nucleus and, thereafter, moved to cytosol
(Figure 4C). These data support the observation that PKA
induces nuclear accumulation of FCoR.
We next examined whether forskolin induced FCoR phos-
phorylation. Sequence analysis revealed a consensus protein
kinase A (PKA) phosphorylation site (R/K-X1–2-S/T-X) at
12
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induced FCoR phosphorylation (Figure 4D) in a H-89-inhibi-
table manner (H89 inhibits PKA) (Figure 4E; Lochner and
Moolman, 2006).
Site-directed mutagenesis of Serine 92 or/and Threonine 93
to Alanine (S92A, T93A, or S92A/T93A) indicated that
Threonine 93, but not Serine 92, is phosphorylated in re-
sponse to forskolin (Figure 4F). To conﬁrm that Threonine 93
is phosphorylated by forskolin, we generated a site-speciﬁc
phospho-T93 antibody (pT93). pT93 immunoreactivity in-
creased in response to forskolin (Figure 4G), suggesting that
the main site of FCoR that is phosphorylated in response to
forskolin is Threonine 93. Furthermore, the PKA catalytic
subunit phosphorylated the GST-WT FCoR fusion protein
directly, but did not phosphorylate GST-T93A or -T93D
FCoR fusion protein (Figure 4H). These data suggest that
PKA directly phosphorylates Threonine 93.
FCoR has a predicted nuclear export signal (NES; amino
acids 78–87) (Supplementary Figure S4A). Indeed, substitu-
tion of Leucine 81 with Alanine enhances FCoR nuclear
translocation and inhibits Foxo1 activity in the absence of
forskolin (Supplementary Figure S4B and C). This indicates
that Leucine 81 is important for NES. We hypothesized that
Threonine 93 phosphorylation affects the subcellular locali-
zation of FCoR. Immunoﬂuorescence of cells transfected with
the T93A and T93D FCoR mutants revealed that T93A FCoR
localized mainly to the cytosol, while T93D FCoR was mainly
in the nucleus (Figure 4I). Furthermore, Western blotting of
cytosolic and nuclear extracts of HEK293 cells transfected
with WT-, T93A-, or T93D-FCoR in the absence of forskolin
supported these ﬁndings (Figure 4J). We performed 5XGAL4
luciferase assays using WT-, T93A-, or T93D-FCoR. FoxO1
increased 5XGAL4 luciferase activity by 17-fold, while co-
transfection with WT FCoR decreased transcriptional activity
by 40%. The T93D-FCoR mutant decreased transcriptional
activity more markedly than WT or T93A-FCoR (Figure 4K).
Inhibition of Foxo1 activity by FCoR reﬂects the Foxo1
acetylation level. An in-vivo acetylation assay in HEK293T
cells demonstrated that T93D FCoR acetylated Foxo1 the
most (Figure 4L). Taken together, these data indicate that
phosphorylation of Threonine 93 induces FCoR nuclear loca-
lization and leads to the acetylation and inhibition of Foxo1.
Finally, to investigate regulation of the interaction between
Foxo1 and FCoR, we performed co-immunoprecipitation
studies with or without forskolin in the presence of serum.
In the presence of forskolin, FCoR did not bind to Foxo1
(Figure 4M, left panel). In contrast, in the absence of for-
skolin, FCoR bound to Foxo1 (Figure 4M, right panel).
Furthermore, in the absence of serum and the presence of
forskolin, FCoR bound to Foxo1 (Figure 2E). These data
indicate that the interaction between FCoR and Foxo1
depends on their subcellular localization.
FCoR is required for adipocyte differentiation
To investigate the physiological role of FCoR in adipocyte
differentiation, we inhibited endogenous FCoR in 3T3-F442A
cells using adenoviruses encoding two kinds of small hairpin
(sh)RNA to decrease FCoR expression (Figure 5B and C;
Supplementary Figure S5B and C). Oil-red O staining revealed
that knockdown of endogenous FCoR inhibited the differen-
tiation of 3T3-F442A cells (Figure 5A; Supplementary Figure
S5A). Analysis of the expression of adipocyte-speciﬁc genes
demonstrated reduced levels of Pparg (Pparg), Glut4 (Slc2a4),
and adiponectin (Adipoq) (Figure 5D; Supplementary Figure
S5D). We showed previously that CN Foxo1 inhibits adipo-
cyte differentiation (Nakae et al, 2003). If FCoR inhibits Foxo-
dependent transcription, then knockdown of FCoR should
enhance the expression of Foxo1-target genes. Indeed, real-
time PCR analysis demonstrated that expression levels of
several Foxo1-target genes increased in cells transduced
with FCoR shRNA compared with scrambled shRNA-
transduced cells (Figure 5E; Supplementary Figure S5E). To
examine whether FCoR interacts with Foxo1 in vivo,w e
performed chromatin immunoprecipitation (Chip) assay
using the p21 (Cdkn1a) promoter (Nakae et al, 2003). The
Chip assay demonstrated that FCoR interacted with Cdkn1a
Figure 3 FCoR enhances Foxo1 acetylation. (A) Effect of FCoR on Foxo1 acetylation. After transfection with pFLAG-CMV2-WT Foxo1 with or
without pCMV5-cMyc-WT FCoR, HEK293 cells were incubated with H2O2 (500mM), nicotinamide (NAM) (50mM), and trichostatin A (TSA)
(2mM) for 3h and harvested. Lysates were immunoprecipitated with anti-FLAG mouse monoclonal antibody (M2) and subjected to western
blotting with the indicated antibodies. The bottom panel shows western blotting of the lysates with and anti-cMyc mouse monoclonal antibody.
(B) FCoR disrupts the interaction between Foxo1 and Sirt1. After transfection with pCMV5-cMyc-WT Foxo1 and pTOPO-Sirt1 with or without
pCMV5-cMyc-WT FCoR, HEK293 cells were incubated with H2O2 for 3h and harvested. Cell lysates were immunoprecipitated with an anti-
cMyc mouse monoclonal antibody and subjected to western blotting with the indicated antibodies. (C) 5XGAL4-luciferase assay of PM-WT,
-6KQ, and -6KR Foxo1. At 36h after transfection with pTAL-5XGAL4, phRL-SV40, and the indicated PM-Foxo1 with or without the FCoR
expression vector, HEK293 cells were incubated with forskolin (20mM) for 6h and harvested. Luciferase activity was measured in the cell
lysates. The grey bar indicates mock-transfected cells and the blue bar indicates pCMV5-cMyc-WT FCoR-transfected cells. Data represent the
mean values±s.e.m. from three independent experiments. Asterisk indicates statistically signiﬁcant difference (*Po0.005 by one-way
ANOVA). (D) Sequence alignment of FCoR with various acetyltransferases. Residues that are identical or chemically similar to those in
mouse FCoR are shown with a red background. FCoR has sequence similarity to the acetyl-CoA binding motifs of the MYST family of HATs
(yeast Esa1, yeast Sas3, Drosophila MOF, human TIP60, and human P/CAF). (E) In-vitro acetylation assay of Foxo1. The GST-Foxo1-C1
(aa251–409) protein was subjected to in-vitro acetylation assays with GST (lanes 1, 4, and 5) or GST-FCoR (lanes 2 and 3) as described in
‘Materials and methods’. Reaction products were analysed by Coomassie brilliant blue staining and autoradiography (
14C). (F) In-vitro
acetylation assay of Foxo1. The GST-Foxo1-C1 (aa251–409) protein was subjected to in-vitro acetylation assays with GST-FCoR (lane 1), GST
(lane 2), or recombinant p300 (lane 3) as described in ‘Materials and methods’. Reaction products were analysed by Coomassie brilliant blue
staining and autoradiography (
14C). (G) Quantiﬁcation of acetylation activity of FCoR. The intensity of each acetylated band and Coomassie
brilliant blue staining band was measured by NIH Image1.62. The relative intensity was corrected by the weight of GST-FCoR or recombinant
p300. Data represent the mean values±s.e.m. from two independent experiments. An asterisk indicates statistically signiﬁcant differences
(*Po0.001 by one-way ANOVA). (H) 5XGAL4-luciferase assay of PM-Foxo1 with pCMV5/cMyc-WT, I78A, T80A, L81A, L85A, and L87A FCoR.
At 36h after transfection with pTAL-5XGAL4, phRL-SV40, and the indicated PM-Foxo1 with or without the FCoR expression vector, HEK293
cells were incubated with forskolin (20mM) for 6h and harvested. Luciferase activity was measured in the cell lysates. Data represent the mean
values±s.e.m. from three independent experiments. Asterisks indicate statistically signiﬁcant differences (*Po0.001 and **Po0.05 by
one-way ANOVA). Figure source data can be found with the Supplementary data.
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Furthermore, adenoviruses encoding FCoR signiﬁcantly en-
hanced acetylation of endogenous Foxo1 at day 4 after
induction of differentiation in 3T3-F442A cells (Figure 5G)
and signiﬁcantly increased Pparg expression at day 10
(Figure 5A; Supplementary Figure S6A).
Foxo1 inhibits the ligand-dependent transcriptional activa-
tion of PPARg. Therefore, if FCoR inhibits Foxo1 activity, then
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Luciferase assay using the J3-tk-Luc reporter vector, which
contains three copies of the PPAR response element (PPRE) of
the apolipoprotein A-II gene J site, demonstrated that FCoR
did not prevent inhibition of PPARg by Foxo1 (Supplementary
Figure S6B). These data suggest that FCoR affects adipocyte
differentiation, but not through the interaction of Foxo1 and
PPARg.
Overexpression of FCoR in WAT decreased adiposity
and increased insulin sensitivity
To study the function of FCoR in vivo, we generated trans-
genic mice that overexpressed FCoR in their adipose tissue
(aP2-cMyc-Fcor: RIKEN Acc. No. CDB0446T) using the 5.4-kb
promoter-enhancer fragment of the mouse aP2 (Figure 6A;
Abel et al, 2001; Imai et al, 2001; He et al, 2003). We
characterized two founder lines; line 1 (WFCoR) showed
greater expression in WAT than in BAT, while the reverse
was true for line N5 (BFCoR) (Figure 6B–D). We thus used
WFCoR to study the role of FCoR in WATand BFCoR to study
the role of FCoR in BAT.
WFCoR mice showed an adult-onset decrease in weight loss
(Figure 6E). CTscan revealed that WFCoR mice had decreased
adipose mass, including the visceral and subcutaneous de-
pots (Figure 6F). Histological analysis of WAT from these
animals demonstrated that the adipocytes in the WAT of
WFCoR mice were similar to WT mice at 12 weeks but the
adipocytes in the WAT of WFCoR mice were smaller than
those from WT mice at 24 weeks (Figure 6G; Supplementary
Figure S7A and B). Although food intake, locomotor activity,
and oxygen consumption were similar to wild-type mice, the
respiratory quotient of WFCoR mice was signiﬁcantly reduced
(Figure 6H, and data not shown). These data indicate in-
creased usage of lipid as an energy source, resulting in lower
body weight.
To investigate the effects of FCoR overexpression in WATon
glucose metabolism, we performed intraperitoneal glucose
(IPGTT) and insulin tolerance test (ITT). Two-month-old
WFCoR mice showed the same glucose tolerance and insulin
sensitivity as wild-type mice (data not shown). However,
4-month-old mice showed evidence of increased glucose
(Figure 6I) and insulin tolerance (Figure 6J). Insulin secretion
in WFCoR mice was similar to that of wild-type mice during
IPGTT (Supplementary Figure S8). These data suggest that
overexpression of FCoR in WAT decreases adiposity and
increases insulin sensitivity in an age-dependent manner.
To investigate the mechanism by which FCoR increases
insulin sensitivity, we examined the expression levels of
adipose tissue-speciﬁc and Foxo1-target genes in WAT. FCoR
transgenic mice showed increased Pparg and decreased
Tnf-a(Tnf), Mcp-1 (Ccl2), and Ccr2 gene expression (Figure 6J
and K). Expression of several Foxo1-target genes (Greer and
Brunet, 2005) was decreased, including the expression of p27
(Cdkn1b), Rb1, p130 (Rbl2), Cyclin G2 (Ccng2), fas ligand
(fasl), Bcl2l11, Gadd45 (Gadd45a), Sod2, and Cat was
decreased (Figure 6L). Acetylation of endogenous Foxo1 in
WAT was signiﬁcantly increased compared with wild-type
mice (Figure 6M). These data suggest that overexpression
Figure 4 FCoR is phosphorylated and translocated into the nucleus in a PKA-dependent manner. (A) Subcellular localization of exogenous
FCoR in HEK293 cells. At 36h after transfection with pCMV5-cMyc-WT FCoR, HEK293 cells were stimulated with forskolin (20mM) for 30min,
ﬁxed, and stained with anti-cMyc mouse monoclonal antibody. (B) Western blotting of cytosolic and nuclear extracts from HEK293 cells
transfected with cMyc-FCoR. At 36h after transfection with pCMV5-cMyc-WT FCoR, HEK293 cells were stimulated with forskolin (20mM) at
the indicated time and harvested. Lysates were fractionated into cytosolic and nuclear extracts and subjected to western blotting with the
indicated antibodies. (C) Immunoﬂuorescence of endogenous FCoR in 3T3-F442A cells. 3T3-F442A cells were cultured and induced
differentiation into mature adipocytes as described in Materials and Methods except supplementation with 500nM of IBMX for 48h.
Thereafter, cells were cultured in DMEM containing 10% fetal calf serum and 1.7mM of insulin. Cells were ﬁxed at the indicated days and
stained with anti-FCoR rabbit polyclonal antibody. (D) Phosphorylation of FCoR by forskolin. After transfection with pCMV5-cMyc-WT FCoR,
HEK293 cells were stimulated with forskolin (20mM) at the indicated time and harvested. Cell lysates were immunoprecipitated with anti-cMyc
mouse monoclonal antibody, subjected to western blotting, and phosphorylated FCoR was detected. (E) Inhibition of phosphorylation of FCoR
by H89. At 48h after transient transfection with pCMV5-cMyc-WT FCoR, HEK293 cells were incubated with or without H89 (1mM) for 3h and
stimulated with forskolin (20mM) for 15min and harvested. Phosphorylated FCoR was detected as described above. (F) Phosphorylation of
mutant FCoR. After transfection with pCMV5-cMyc-WT (lanes 1 and 2), S92A (lanes 3 and 4), T93A (lanes 5 and 6), or S92A/T93A (lanes 7 and
8) FCoR, HEK293 cells were stimulated with forskolin (20mM) for 15min. Phosphorylated FCoR was detected as described above. (G) Detection
of phosphorylated Threonine 93 by anti-phospho-T93-speciﬁc (anti-pT93) antibody. At 48h after transfection with pCMV5-cMyc-WT FCoR,
HEK293 cells were incubated with or without H89 (1mM) for 3h and stimulated with or without forskolin (20mM) for 15min and harvested.
Lysates were subjected to western blotting with anti-pT93. (H) In-vitro phosphorylation assay of FCoR. GST, GST-WT, GST-T93A, GST-T93D
FCoR, and GST-RRAS, which is a short sequence of salt-inducible kinase (SIK) 2, was phosphorylated in vitro by incubating with a catalytic
subunit from cAMP-dependent protein kinase as described in ‘Materials and methods’. Reaction products were subjected to western blotting,
phosphorylated products were detected using Phos-tag
R BTL-104 (top panel) and then blotted with anti-GST antibody (bottom panel).
(I) Subcellular localization of exogenous T93A (the top panel) or T93D FCoR (the bottom panel) in HEK293 cells. At 36h after transfection with
pCMV5-cMyc-T93A or T93D FCoR, HEK293 cells were ﬁxed as described in Materials and methods and stained with anti-cMyc mouse
monoclonal antibody. (J) Western blotting of cytosolic and nuclear extracts from HEK293 cells transfected with cMyc-WT (lanes 1 and 2), T93D
(lanes 3 and 4), or T93A (lanes 5 and 6) FCoR. At 36h after transfection, HEK293 cells were harvested. Lysates were fractionated into cytosolic
and nuclear extracts and subjected to western blotting with the indicated antibodies. (K) 5XGAL4-luciferase assay of PM-Foxo1 with pCMV5/
cMyc-WT, T93A, and T93D FCoR. At 36h after transfection with pTAL-5XGAL4, phRL-SV40, and the indicated PM-Foxo1 with or without the
FCoR expression vector, HEK293 cells were incubated with forskolin (20mM) for 6h and harvested. Luciferase activity was measured in the
lysates. Data represent the mean values±s.e.m. from three independent experiments. Asterisks indicate statistically signiﬁcant difference
(*Po0.001, **Po0.005, and ***Po0.05 by one-way ANOVA). (L) The T93D FCoR mutant acetylates Foxo1 the most. After transfection with
pFLAG-CMV2-WT Foxo1 with or without pCMV5-cMyc-WT (lane 4), T93A (lane 5), or T93D (lane 6) FCoR, HEK293 cells were incubated with
(lanes 3–6) or without H2O2 (lanes 1 and 2) (500mM), nicotinamide (NAM) (50mM), and trichostatin A (TSA) (2mM) for 3h and harvested.
Lysates were immunoprecipitated with anti-FLAG mouse monoclonal antibody (M2) and subjected to western blotting with the indicated
antibodies. (M) Interaction between Foxo1 and FCoR. HEK293 cells were co-transfected with pCMV5-cMyc-Foxo1 and pFLAG-CMV2-WTFCoR
and culture at the indicated condition. Cell lysates were immunoprecipitated with anti-FLAG, anti-cMyc or normal mouse IgG and blotted with
anti-cMyc or anti-FLAG antibody. Figure source data can be found with the Supplementary data.
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decreases the size of adipocytes in WAT, and increases insulin
sensitivity.
We crossed Lepr
db/þ-WFCoR with Lepr
db/þ mice and gen-
erated Lepr
db/db-WFCoR mice in order to investigate whether
overexpression of FCoR in WAT improves glucose metabo-
lism in Lepr
db/db mice. Lepr
db/db-WFCoR mice showed a
signiﬁcant decrease in body weight compared with Lepr
db/db
mice (Supplementary Figure S9A and B). IPGTT and ITT
demonstrated that Lepr
db/db-WFCoR mice have improved
glucose tolerance and insulin sensitivity (Supplementary
Figure S9C and D). CT scans revealed decreased visceral fat
mass in Lepr
db/db-WFCoR compared with Lepr
db/db mice,
despite similar total adipose tissue mass (Supplementary
Figure S9E). Measurement of adipocyte size revealed that
white adipocytes from Lepr
db/db-WFCoR mice were signiﬁ-
cantly smaller than those from Lepr
db/db (Supplementary
Figure S9F–H). Although the food intake and respiratory
quotient of Lepr
db/db-WFCoR mice were similar to Lepr
db/db
mice, oxygen consumption was signiﬁcantly increased (data
not shown; Supplementary Figure S9I). Gene expression
analysis demonstrated that the expression levels of Ccl2 and
several Foxo1-target genes were decreased signiﬁcantly com-
pared with levels in Lepr
db/db mice (Supplementary Figure
S9J–L). These data suggest that the FCoR in WATcan improve
glucose metabolism in Lepr
db/db mice.
We next examined the effects of overexpression of FCoR in
mice with diet-induced obesity. The WFCoR mice had a lean
phenotype compared with wild-type mice fed a HFD and had
smaller adipocytes in WAT (Supplementary Figure S10A and
B). IPGTT and ITT revealed that HFD WFCoR mice had
improved glucose tolerance and insulin sensitivity compared
with wild-type mice (Supplementary Figure S10C and D).
These ﬁndings are in accordance with the idea that FCoR in
WAT improves insulin sensitivity.
FCoR in BAT affects thermoregulation
We also analysed BAT function in BFCoR mice (Figure 6B–D).
BFCoR mice have normal body weight (Supplementary
Figure S11A) and IPGTT (Supplementary Figure S11B).
Insulin sensitivity was similar to wild-type mice
(Supplementary Figure S11C). We also measured oxygen
consumption to investigate the effects of overexpression of
FCoR on the physiological function of BAT. Oxygen consump-
tion and the respiratory quotient of BFCoR mice were similar
to wild-type mice (Supplementary Figure S11D and E). The
BFCoR mice exhibited signiﬁcantly reduced cold tolerance
compared with wild-type mice (Figure 7A). We detected
B60% and B50% decreases of Ppargc1a and Ucp1, respec-
tively (Figure 7B), in BFCoR mice, along with a commensu-
rate decrease in PGC-1a protein (Figure 7C). Furthermore,
BFCoR mice exhibited reduced expression levels of mitochon-
drial components (Figure 7D). These data indicate that over-
expression of FCoR in BAT suppresses thermoregulation by
suppressing PGC-1a expression.
FCoR regulates PGC-1a gene expression
To examine whether FCoR can suppress Ppargc1a expression
at the cellular level, we transduced the brown adipocyte cell
line T37i cells with adenovirus encoding LacZ or cMyc-FCoR
and examined endogenous Ppargc1a expression. Real-time
PCR showed that overexpression of FCoR suppressed endo-
genous Ppargc1a expression in T37i cells in an FCoR dose-
dependent manner (Figure 7E). The PGC-1a protein level was
also decreased by FCoR expression in T37i cells (Figure 7F).
To investigate whether FCoR suppresses Ppargc1a promoter
activity, we performed a luciferase reporter assay using
truncated versions of Ppargc1a promoters. The Ppargc1a
promoter has two insulin-responsive elements, IRE1 and
IRE2 (Figure 7G). To characterize the FCoR-target site in the
Ppargc1apromoter, we constructed different versions of the
mouse Ppargc1a promoter by progressively deleting portions
of its upstream region. The transcriptional activity of each
mutant promoter in response to FCoR was examined in T37i
cells (Figure 7G). Mutant promoters with deletions up to –
890nt in the Ppargc1a promoter, which includes IRE1 and/or
IRE2, still responded to FCoR. However, further deletion up
to –483nt, which has no IRE, completely abolished the
Figure 5 The effects of knockdown of FCoR on adipocyte differentiation. (A) Oil-red O staining of 3T3-F442A cells. At day 14 after induction of
differentiation and transduction with adenoviruses encoding scrambled (the top panel), shRNA1 (the middle panel), and cMyc FCoR (the
bottom panel), cells were stained with Oil-red O. (B) Knockdown of endogenous Fcor mRNA in 3T3-F442A cells during differentiation. 3T3-
F442 cells were induced to differentiation into mature adipocytes as described in ‘Supplementary Experimental Procedures’ and transduced
with adenovirus encoding shRNA1 (blue bar) or scrambled shRNA (grey bar). Total RNA was isolated from cells on the indicated day and
subjected to real-time PCR of Fcor and b-actin. The data were corrected using the b-actin expression level and represent the mean
values±s.e.m. from two independent experiments. Asterisks indicate statistically signiﬁcant differences between Fcor expression levels in
scrambles- and shRNA1-transduced cells (*Po0.001 by one-way ANOVA). (C) Western blotting of endogenous FCoR protein. On day 10 after
transduction with adenovirus encoding scrambled or shRNA1, 3T3-F442A cells were harvested and the lysates were subjected to western
blotting with the indicated antibodies. (D) Effects of knockdown of FCoR on the expression of adipocyte-speciﬁc genes during differentiation of
3T3-F442A cells. After induction of differentiation and transduction, total RNA was isolated on the indicated days and subjected to real-time
PCR of Pparg (top panel), Slc2a4 (middle panel), and Adipoq (bottom panel). The grey bar indicates scrambled-transduced cells and the blue
bar indicates shRNA1-transduced cells. The data were corrected using the b-actin expression level and represent the mean values±s.e.m. from
two independent experiments. Asterisks indicate statistically signiﬁcant difference between scrambled- and shRNA1-transduced cells
(*Po0.001, **Po0.005, and ***Po0.01 by one-way ANOVA). (E) Effects of knockdown of FCoR on the expression levels of Foxo1-target
genes during differentiation of 3T3-F442A cells. Total RNA from scrambled- (grey bar) or shRNA1-transduced cells (blue bar) on the indicated
days was subjected to real-time PCR of the indicated Foxo1-target genes. The data were corrected using the b-actin expression level and
represent the mean values±s.e.m. from two independent experiments. Asterisks indicate statistically signiﬁcant difference between scrambled-
and shRNA1-transduced cells (*Po0.001 and **Po0.005 by one-way ANOVA). (F) Chromatin immuunoprecipitation (Chip) assay of the
Cdkn1a promoter. The Chip assay was performed using 3T3-F442A cells during (lane 1) or at the end of clonal expansion (lane 2) with the
indicated antibodies. The lower panel shows western blotting of 3T3-F442A cells lysates at the indicated period with the indicated antibodies.
(G) Acetylation of endogenous Foxo1 in 3T3-F442A cells transduced with adenoviruses encoding LacZ (lanes 1–4) or cMyc-FCoR (lanes 5–8)
during differentiation. After induction of differentiation and transduction, cells were harvested on the indicated day, immunoprecipitated with
anti-FOXO1 antibody, and blotted with the indicated antibodies.
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(Figure 7G). Thus, the FCoR-target site was conﬁned to a
proximal in the mouse Ppargc1a promoter and FCoR sup-
pressed Ppargc1a promoter activity. These data indicate that
FCoR inhibits Ppargc1a expression. Using Chip assays, we
investigated two IREs in the Ppargc1a promoter. Chip
assays using both promoter regions revealed that FCoR
bound the proximal IRE2 but not the distal IRE1
(Figure 7H). These data suggest that FCoR binds to the
Ppargc1a promoter via IRE2.
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To investigate the physiological roles of FCoR, we generated
Fcor knockout (FcorKO) mice (Supplementary Figure S12A–
E). FcorKO mice had a lean phenotype, glucose intolerance,
and insulin resistance on a normal chow diet (Figure 8A–C).
CT scan revealed that FcorKO mice had adipose mass that
was similar to that of WT mice, including the visceral and
subcutaneous depots (data not shown). In contrast to
our ﬁndings that FCoR is overexpressed in WAT, the size of
epididymal fat adipocytes was larger in FcorKO mice than
in wild-type mice (Figure 8D and E). These data suggest
that there may be fewer adipocytes in FcorKO mice than in
WT mice. The expression of several Foxo-target genes
was signiﬁcantly increased in both WAT and BAT in FcorKO
mice (Figure 8F and G). The expression levels of WAT-
speciﬁc genes were similar in FcorKO mice as in wild-type
mice, but the expression levels of inﬂammatory genes,
including Emr1 and Ccr2, were signiﬁcantly increased
(Figure 8H and I), leading to insulin resistance (Olefsky and
Glass, 2010).
Although the food intake of FcorKO mice was similar to that
of wild-type mice, oxygen consumption was signiﬁcantly
increased and respiratory quotient was signiﬁcantly de-
creased (Figure 8J–L). These data indicate that FcorKO mice
had increased energy expenditure and increased usage of fat
that led to a lean phenotype.
Overexpression of FCoR suppressed PGC-1a expression in
BFCoR mice and T37i cells. Therefore, deletion of Fcor would
be expected to increase PGC-1a expression. Indeed, the
expression levels of Ppargc1a and the PGC-1a protein in the
BAT of FcorKO mice were signiﬁcantly increased compared
with wild-type mice (Figure 8M and N). These data conﬁrm
that FCoR suppresses the transcriptional activity of Foxo1 and
PGC-1a expression.
Discussion
Using a two-hybrid screen, we identiﬁed a Foxo1-
CoRepressor termed as FCoR that is expressed in adipose
tissue, inhibits Foxo1 transcriptional activity, and is phos-
phorylated by PKA and then translocated into the nucleus.
FCoR is activated in a fasting or starved state, or during cold
exposure, all conditions in which PKA is activated by gluca-
gon or adrenergic stimuli. Thus, FCoR may be an important
metabolic regulator that coordinates the insulin/cAMP
response by interacting with Foxo. However, at fasting
state, expression level of activated FCoR protein is decreased.
We speculate that the active, presumed phosphorylated,
FCoR protein is unstable and turned over rapidly.
Experiments showed that FCoR prevents Sirt1 binding to
Foxo1, thus enhancing Foxo1 acetylation and inhibiting its
transcriptional activity. Several proteins have been reported
to affect Foxo1 and Sirt1. In C. elegans, two 14-3-3 proteins
bind to SIR-2.1 and DAF-16 and are required for SIR-2.1-
induced transcriptional activation of DAF-16 (Berdichevsky
et al, 2006). Furthermore, four-and-a-half LIM 2 (FHL2) also
interacts with FOXO1; FHL2 enhances the interaction
between FOXO1 and SIRT1 and therefore enhances the
deacetylation of FOXO1 (Yang et al, 2005). To date, FCoR is
the only protein that is known to inhibit the interaction of
Sirt1 and Foxo1.
Figure 6 Generation of transgenic mice expressing wild-type FCoR driven by the aP2 promoter. (A) Diagram of the transgenic construct. In
addition to 5.4kb of the aP2 promoter, the construct contains the cMyc-WT Fcor cDNA and the human GH polyadenylation sequences.
(B) Tissue survey of transgene expression in WAT (lanes 1 and 6), BAT (lanes 2 and 7), liver (lanes 3 and 8), skeletal muscle (lanes 4 and 9),
and hypothalamus (lanes 5 and 10) in line N5 (lanes 1–5) and line 1 (lanes 6–10). Total RNA was isolated from the tissues indicated at the
bottom of the autoradiogram and analysed by northern blotting using Fcor or b-actin cDNA probe. (C) Real-time PCR of transgene expression in
WATand BAT from transgenic lines. Data represent the mean values±s.e.m. of RNA samples from each of ﬁve transgenic mice for each tissue.
The grey, sky blue, and red bars indicate wild-type, aP2-FCoR-1 (WFCoR), and aP2-FCoR-N5 (BFCoR), respectively. (D) Western blotting of
transgenic cMyc-FCoRexpression in WAT (lanes 1–3) and BAT (lanes 4–6). Lysates from the tissue of the indicated types of mice were subjected
to western blotting with the indicated antibodies. (E) Body weight of wild-type and transgenic mice (WFCoR) fed a normal chow diet. Data
represent the mean values±s.e.m. of 15–20 male mice for each genotype. The open and closed circles indicate wild-type and WFCoR mice,
respectively. An asterisk indicates a statistically signiﬁcant difference between wild-type and WFCoR (*Po0.01 by one-way ANOVA).
(F) Adiposity of 5-month-old WFCoR transgenic mice fed a normal chow diet. Skeletal muscle mass, adipose tissue mass (sum of visceral
and subcutaneous fat mass), visceral fat mass, and subcutaneous fat mass were calculated. The data are reported as percentage of body weight
and represent the mean±s.e.m. of ﬁve mice of each genotype. Asterisks indicate statistically signiﬁcant differences between wild-type and
WFCoR mice (*Po0.02 and **Po0.05 by one-way ANOVA). (G) Average of size of adipocytes from epididymal fat of 5-month-old wild-type
(grey bar) and WFCoR (sky blue bar) mice fed a normal chow diet. An asterisk indicates a statistically signiﬁcant difference between wild-type
and WFCoR mice (*Po0.001 by one-way ANOVA). (H) Food intake, oxygen consumption, and respiratory quotient of 5-month-old wild-type
(grey bar) and WFCoR (sky blue bar) mice fed a normal chow diet. An asterisk indicates a statistically signiﬁcant difference between wild-type
and WFCoR mice (*Po0.001 by one-way ANOVA). (I) Intraperitoneal glucose tolerance test in wild-type (n¼10) and WFCoR transgenic mice
(n¼10) fed a normal chow diet. The open and closed circles indicate wild-type and WFCoR mice, respectively. Data represent the mean
values±s.e.m. Asterisks indicate statistically signiﬁcant differences between wild-type and WFCoR mice (*Po0.005 and **Po0.02 by one-way
ANOVA). (J) Intraperitoneal insulin tolerance test in wild-type (n¼8) and WFCoR (n¼10) mice fed a normal chow diet. Data represent the
mean values±s.e.m. Asterisks indicate statistically signiﬁcant differences between wild-type and WFCoR mice (*Po0.005 and **Po0.05 by
one-way ANOVA). (K) Real-time PCR of WAT-speciﬁc genes using WAT from wild-type (grey bar) and WFCoR transgenic mice (sky blue bar) fed
a normal chow diet. Data represent the mean values±s.e.m. of RNA samples from ﬁve mice of each genotype. An asterisk indicates a
statistically signiﬁcant difference between wild-type and WFCoR transgenic mice (*Po0.05 by one-way ANOVA). (L) Real-time PCR of Ccl2,
Emr1, and Ccr2 genes using WAT from wild-type (grey bar) and WFCoR transgenic mice (sky blue bar) fed a normal chow diet. Data represent
the mean values±s.e.m. of RNA samples from ﬁve mice of each genotype. Asterisks indicate statistically signiﬁcant differences between wild-
type and WFCoR transgenic mice (*Po0.001 and **Po0.005 by one-way ANOVA). (M) Real-time PCR of Foxo1-target genes using WAT from
wild-type (grey bar) and WFCoR transgenic mice (sky blue bar). Data represent the mean values±s.e.m. of RNA samples from ﬁve mice of each
genotype. Asterisks indicate statistically signiﬁcant differences between wild-type and WFCoR transgenic mice (*Po0.001 and **Po0.005 by
one-way ANOVA). (N) Acetylation of endogenous Foxo1 in WAT from 5-month-old wild-type (lane 1) and WFCoR transgenic mice (lane 2).
Tissue lysates containing nicotinamide (NAM) (50mM) and trichostatin A (TSA) (2mM) were immunoprecipitated with anti-FOXO1 antibody
and blotted with the indicated antibodies.
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Figure 7 FCoR in BAT affects thermoregulation through suppression of Ppargc1a expression. (A) Changes in the rectal temperature of
6-month-old wild-type (open circle) and BFCoR (closed circle) mice after cold exposure. Data represent the mean values±s.e.m. (n¼6 for each
genotype). Asterisks indicate statistically signiﬁcant differences between wild-type and BFCoR transgenic mice (*Po0.05 by one-way ANOVA).
(B) Real-time PCR of Ppargc1a and Ucp1 in BAT from wild-type (grey bar) and BFCoR transgenic mice (red bar). The data were corrected using
the b-actin expression level and represent the mean values±s.e.m. of three independent experiments (n¼6 for each genotype). Asterisks
indicate statistically signiﬁcant differences between wild type and BFCoR transgenic mice (*Po0.05 by one-way ANOVA). (C) Western blotting
of PGC-1a and UCP-1 protein in BAT from wild-type (lane 1) and BFCoR transgenic mice (lane 2). Lysates (200mg) of BAT from wild-type and
BFCoR transgenic mice were subjected to western blotting with the indicated antibodies. (D) Real-time PCR of mitochondrial component genes
using BAT from wild-type (grey bar) and BFCoR transgenic mice (red bar). Data represent the mean values±s.e.m. of RNA samples from ﬁve
mice of each genotype. Asterisks indicate statistically signiﬁcant differences between wild-type and BFCoR transgenic mice (*Po0.001 and
**Po0.005 by one-way ANOVA). (E) The effects of overexpression of cMyc-FCoR on endogenous Ppargc1a gene expression in T37i cells. T37i
cells were transduced with adenovirus encoding LacZ or cMyc-FCoR. Cells were harvested 48h after transduction. Total RNAwas isolated and
subjected to real-time PCR of Ppargc1a. Data were corrected using the b-actin expression level, shown as ‘fold change0 compared with LacZ-
transduced cells, and represent the mean values±s.e.m. from three independent experiments. An asterisk indicates a statistically signiﬁcant
difference between LacZ- and cMyc-FCoR-transduced cells (*Po0.001 by one-way ANOVA). (F) PGC-1a protein expression was decreased in a
dose-dependent manner by overexpression of FCoR in T37i cells. (G) Effect of FCoR on Ppargc1a promoter activity. Data were obtained in ﬁve
experiments and are represented as the mean values±s.e.m. of fold change compared with mock vector-transfected activity in T37i cells
transfected with truncated Ppargc1a (S3). *Po0.001 (one-factor ANOVA of cells transfected with pCMV5/cMyc and with pCVM5/cMyc-FCoR
vector). (H) Chip assays of T37i cells transduced with an adenovirus encoding cMyc-FCoR and harvested 36h after transduction. The PCR
primers used to amplify the mouse Ppargc1a promoter sequence as indicated as S3 and S4. PCRss with total input chromatin are shown as
controls. Figure source data can be found with the Supplementary data.
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and class I HDAC (HDAC3) are critical components of the
transcriptional response to fasting in liver, shuttling into the
nucleus in response to forskolin or glucagon. HDAC4 and 5
induces the acute transcription of gluconeogenic enzymes
such as G6Pase via deacetylation and activation of Foxo
family transcription factors (Mihaylova et al, 2011; Wang
et al 2011). In the present study, we used trichostatin A
(TSA) for the prevention of deacetylation of Foxo1.
Therefore, we cannot exclude the possibility that FCoR
works on the regulatory complex with the class IIa and I
HDACs. It is established that in hepatocytes, Foxo is actively
promoting transcription of its target genes after forskolin,
glucagon, or cAMP treatment. However, Fcor is expressed
little in liver of wild-type mice under normal chow diet. If
FCoR is expressed in liver, then the predicted acetylation and
inhibition of Foxo may run counter to the known activation of
Foxo by forskolin/cAMP agonists.
Interestingly, FCoR itself has intrinsic acetyltransferase
activity. Acetylation represents a fail-safe mechanism for
preventing excessive Foxo1 activity (Banks et al, 2011).
Therefore, FCoR may maintain Foxo1 acetylation by direct
acetylation in the cytosol in the fed state and by interruption
of the association of Foxo1 with Sirt1 in the nucleus in a
fasting or starved state or during cold exposure. This is
consistent with the idea that FCoR acts to ﬁne-tune Foxo1
activity (Figure 9). FCoR can also acetylate other transcrip-
tion factors and cofactors (Nakae et al, unpublished observa-
tion). Therefore, the sudden decline of body weight in WFCoR
mice may be due to acetylation of other binding partners of
FCoR. Further investigation of FCoR-binding proteins is
needed to identify such partners.
The ﬁnding that knockdown of endogenous FCoR inhibited
the differentiation of 3T3-F442A cells suggests that FCoR is
indispensable for adipocyte differentiation. This is in keeping
with our previous ﬁndings that overexpression of CN Foxo1
(ADA) inhibits the differentiation of 3T3-F442A cells (Nakae
et al, 2003). Jing et al reported that the KR mutant of Foxo1,
which is activated and thus mimics the deacetylated protein
(Banks et al, 2011), inhibits adipocyte differentiation (Jing
et al, 2007). Therefore, knockdown of FCoR may accelerate
Foxo1 deacetylation and so inhibit adipogenesis.
The present study demonstrated that while FCoR over-
expression decreased the adipocyte size in transgenic mice,
FcorKO mice exhibited increased adipocyte size, consistent
with ﬁndings for Foxo1 haploinsufﬁciency or transgenic mice
overexpressing a dominant-negative Foxo1 mutant in fat cells
(aP2-FLAG-D256) (Nakae et al, 2003, 2008a; Kim et al, 2009).
Namely, inhibition of Foxo1 leads to smaller adipocytes.
Therefore, inhibition of Foxo1 by overexpression of FCoR
reduces adipocyte size. On the other hand, activation of
Foxo1 by deletion of FCoR increases adipocyte size. Foxo1
is involved in the early stages of adipose conversion (Nakae
et al, 2003). Therefore, it is speculated that generation of
adipocytes in FcorKO mice is decreased due to activation of
Foxo1. Previous reports showed that Foxo1 inhibits PPARg
activity (Dowell et al, 2003; Armoni et al, 2006; Fan et al,
2009). Knockdown of FCoR should enhance Foxo1 activity,
leading to inhibition of PPARg and adipogenesis. However, in
the present study, FCoR did not prevent Foxo1-induced
inhibition of PPARg activity. More than that, knockdown of
Fcor suppressed Pparg gene expression in 3T3-F442A cells
and overexpression of FCoR in WAT signiﬁcantly increased
Pparg expression. Foxo1 represses transcription from either
Pparg1 or Pparg2 promoter (Armoni et al, 2006). Therefore,
inhibition of Foxo1 by FCoR may work on Pparg promoter
and increase Pparg expression, leading to enhanced
adipogenesis and smaller adipocytes.
We found that FCoRexpression in BATof transgenic mice led
to cold intolerance and to decreased expression levels of
Ppargc1a and Ucp1, suggesting that FCoR regulates brown
adipocyte function. FCoR expression is induced by cold expo-
sure. Therefore, FCoR in BAT may restrict mitochondrial bio-
genesis during cold exposure by inhibition of Ppargc1a
expression. However, the ﬁndings are inconsistent with our
previous report that aP2-FLAG-D256 mice, in which a transac-
tivation-defective Foxo1 (D256) is expressed in both WAT and
BAT, showed increased oxygen consumption accompanied by
increased expression of PGC-1a, uncoupling protein (UCP)-1,
UCP-2, and b3-adrenergic receptor (b3-AR) (Nakae et al,
2008a). If FCoR works by inhibiting Foxo1 activity in BAT,
then overexpression of FCoR should enhance the thermogenic
function of BAT, leading to increased expression of Ppargc1a
and increased energy expenditure. Therefore, FCoR may inhibit
Ppargc1a expression via other partners but not via inhibition of
Foxo1 in BAT. However, in liver, Ppargc1a is a transcriptional
target that is induced by the dephosphorylation mutant of
Foxo1 (Daitoku et al, 2003; Matsumoto et al, 2006). Further
investigation is needed to clarify the molecular target of FCoR
in the Ppargc1a promoter in BAT.
FCoR acts as a ‘repressor’ of Foxo1 and Foxo3a but not of
Foxo4. The failure to identify homologous genes in C. elegans,
along with the repression of FCoR expression in states of food
deprivation, indicates that FCoR may act as an anti-thrifty
gene. FCoR regulates insulin sensitivity by altering the size of
white adipocytes in WAT and induces cold intolerance by
inhibiting Ppargc1a expression. FCoR is thus an attractive
therapeutic target for treatment of obesity and type 2 diabetes.
Materials and methods
Antibodies and cell cultures
Anti-FCoR antisera were raised by immunizing rabbits with a
peptide corresponding to amino acids 2–16 of the mouse FCoR
sequence (GGPTRRHQEEGSAEC). Phospho-threonine 93 rabbit
polyclonal antibodies (anti-pT93) were produced by immunizing
rabbits with a synthetic phosphorylated peptide coupled to KLH
that corresponded to amino acids 85–94 surrounding mouse FCoR
Threonine 93 (LDLNSQRS-T (PO3H2)-C). Antibodies were puriﬁed
using Activated Thiol-Sepharose 4B (Pharmacia) Peptide Columns
and peptide afﬁnity chromatography (TAKARA BIO, Inc.). We
purchased anti-FLAG (M2) and anti-tubulin from Sigma; anti-
cMyc (9E10), anti-FOXO1 (H128), anti-PGC-1 (H300), and anti-
GST (Z-5) from Santa Cruz Biotechnology; and anti-phospho-
FOXO1 (pT24), and anti-acetylated lysine polyclonal antibodies
from Cell Signaling Technology. HEK293 cells and T37i cells were
cultured as described previously (Nakae et al, 1999, 2008a).
Preadipocytes cell line 3T3-F442A cells were cultured and induced
differentiation into mature adipocytes as described previously
(Nakae et al, 2003). Staining 3T3-F442A cells with oil red O was
described previously (Nakae et al, 2003).
Yeast two-hybrid screen
Amino acids 1–154 of murine Foxo1 were cloned in-frame into the
GAL4 DNA-binding domain plasmid pGBKt7 (Clontech). The GAL4
activation domain 3T3-L1 cDNA library of 3T3-L1 was the kind gift of
Dr Alan R Saltiel (University of Michigan Medical Center, Michigan,
USA) (Printen et al, 1997). The AH109 yeast strain was used for the
library search. The transformation was performed as described in the
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transformants were plated on SD/-Ade/-His/-Leu/-Tyr plates in the
presence of galactose and then were incubated at 301Cf o r3 – 4d a y s .
Positive interaction was identiﬁed by strong b-galactosidase activity.
Individual positive clones were isolated using the Yeastmaker yeast
plasmid isolation kit (BD Bioscience), sequenced by an ABI310
automated DNA sequencer, and analysed for homology with
sequences in the GenBank database using the BLAST algorithm.
Rapid ampliﬁcation of cDNA ends
In order to determine the complete 50 and 30 sequence of Fcor
mRNA, we performed both 50- and 30-RACE using the SMART RACE
cDNA Ampliﬁcation Kit (Clontech) according to manufacturer’s
protocol. In brief, we isolated total RNA from the WAT and BAT of
wild-type mice and synthesized ﬁrst-strand cDNA. After that, we
performed 50- and 30-RACE PCR using the following gene speciﬁc
primers: 50-CACCACTACCATCACCACACTGCACCGG-30 for 50-RACE
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RACE PCR. The PCR products were separated by electrophoresis
in a 1.5% agarose gel (Supplementary Figure 1B). After puriﬁcation
using the QIAquick
R Gel Extraction Kit (QIAGEN), PCR products
were subcloned into the pCRII
R vector (Invitrogen) using the TA
Cloning Kit
R (Invitrogen) and sequenced.
Figure 8 Deletion of Fcor induces insulin resistance. (A) Body weight of wild-type and FcorKO mice fed a normal chow diet. Data represent the
mean values±s.e.m. of 20–30 male mice for each genotype. The open and yellow closed circles indicate wild-type and FcorKO mice,
respectively. An asterisk indicates statistically signiﬁcant difference between wild-type and FcorKO (*Po0.01 by one-way ANOVA).
(B) Intraperitoneal glucose tolerance test in wild-type (n¼10) and FcorKO mice (n¼10) under normal chow diet. The open and yellow
closed circles indicate wild-type and FcorKO mice, respectively. Data represent mean values±s.e.m. Asterisks indicate statistically signiﬁcant
differences between wild-type and FcorKO mice (*Po0.001 and **Po0.02 by one-way ANOVA). (C) Intraperitoneal insulin tolerance test in
wild-type (n¼10) and FcorKO (n¼10) fed a normal chow diet. Data represent the mean values±s.e.m. Asterisks indicate statistically
signiﬁcant differences between wild-type and FcorKO mice (*Po0.005 and **Po0.05 by one-way ANOVA). (D) Distribution of adipocyte size.
The sizes of single adipocytes from 5-month-old wild-type (grey bar) or FcorKO (yellow bar) mice fed a normal chow diet were measured as
described in ‘Supplementary Experimental Procedures’. The data represent the mean values±s.e.m. of the percentage of all adipocytes with the
indicated size. Asterisks indicate statistically signiﬁcant differences between wild-type and FcorKO mice (*Po0.05 by one-way ANOVA).
(E) The average of size of adipocytes from (D). An asterisk indicates a statistically signiﬁcant difference between wild-type and FcorKO mice
(*Po0.005 by one-way ANOVA). (F, G) Real-time PCR of Foxo1-target genes using WAT (F) and BAT (G) from wild-type (grey bar) and FcorKO
(yellow bar) mice. Data represent the mean±s.e.m. of RNA samples from 10 mice of each genotype. Asterisks indicate statistically signiﬁcant
differences between wild-type and WFCoR transgenic mice (*Po0.05 by one-way ANOVA). (H) Real-time PCR of WAT-speciﬁc genes using WAT
from wild-type (grey bar) and FcorKO (yellow bar) mice fed a normal chow diet. Data represent the mean values±s.e.m. of RNA samples from
ﬁve mice of each genotype. (I) Real-time PCRof Ccl2, Emr1, and Ccr2 genes using WAT from wild-type (grey bar) and FcorKO (yellow bar) mice.
Data represent the mean values±s.e.m. of RNA samples from ﬁve mice of each genotype. Asterisks indicate statistically signiﬁcant differences
between wild-type and FcorKO mice (*Po0.05 by one-way ANOVA). (J) Food intake of 5-month-old wild-type (grey bar) and FcorKO (yellow
bar) mice. Data represent the mean values±s.e.m. of food intake for 4 days. (K, L) The effects of deletion of Fcor on energy expenditure.
Average oxygen consumption (K) and respiratory quotient (L) of 5-month-old wild-type (grey bar) and FcorKO (yellow bar) mice fed a normal
diet. Data represent the mean values±s.e.m. of six male mice for each genotype. Measurements of oxygen consumption were performed for
72h after allowing the mice to acclimate to the cage environment. An asterisk indicates a statistically signiﬁcant difference between wild-type
and FcorKO mice (*Po0.05 by one-way ANOVA). (M) Western blotting of PGC-1a (top panel) and tubulin (bottom panel) in BAT from wild-type
(lanes 1–3) and FcorKO (lanes 4–7) mice. (N)R e a l - t i m eP C Ro fPpargc1a and Ucp1 using BAT from wild-type (grey bar) and FcorKO (yellow bar)
mice. Data represent the mean values±s.e.m. of RNA samples from 10 mice of each genotype. Asterisks indicate statistically signiﬁcant differences
between wild-type and WFCoR transgenic mice (*Po0.05 by one-way ANOVA). Figure source data c a nb ef o u n dw i t ht h eS upplementary data.
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Figure 9 A model for the roles of FCoR in ﬁne-tuning of Foxo1 activity. (A) When mice are in the fed state, Foxo1 is phosphorylated and FCoR
expression is increased. Both proteins remain in the cytosol. FCoR acetylates Foxo1 directly and keeps it in the acetylated state. (B) When mice
are in the fasting state, insulin level decreases and Foxo1 remains in the nucleus and is activated. At the same time, glucagon from pancreatic
a-cells is increased and activates cAMP-dependent protein kinase (PKA). Furthermore, upon exposure to the cold, adrenergic stimuli also
activate PKA. These events lead to the nuclear localization of FCoR, which increases acetylation of Foxo1 by interrupting the association
between Foxo1 and Sirt1. FCoR thus regulates energy storage, energy expenditure, and insulin sensitivity by ﬁne-tuning Foxo1 function.
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Isolation of total RNA from tissues and cells was performed using
the SV Total RNA Isolation System (Promega) according to manu-
facturer’s protocol. Real-time PCR was performed as described
previously (Nakae et al, 2008a). The primers used in this study
are described in Table S1. We used the following primers
for ampliﬁcation of Fcor:5 0-ATGGGCGGTCCTACACGCCGCCAT-30
(sense) and 50-CTAGCACATGCCTTTAGTCCC-30 (antisense).
Northern blotting was performed using standard techniques. To
prepare the probe for Fcor, we performed PCR using pCMV5/cMyc-
FCoR plasmid as a template and the same primers as in real-time
PCR. The probe used here for b-actin was described previously
(Nakae et al, 2008a).
Construction of expression vectors
To construct pCMV5/cMyc-FCoR, we reverse transcribed total RNA
from mouse BATs using the GeneAmpR RNA PCR Core Kit (Applied
Biosystems) and performed PCR using the following primers: 50-GG
TCTAGA (XbaI) ATGGGCGGTCCTACACGCCGC-30 (FCoR-S) and
50-GG TCTAGA (XbaI) CTAGCACATGCCTTTAGTCCC-30 (FCoR-AS).
After treatment with XbaI, PCR products were subcloned into the
XbaI-treated pCMV5/cMyc vector (Nakae et al, 1999). To construct
pFLAG-CMV2-FCoR, we performed PCR using pCMV5/cMyc-FCoR
as a template and FCoR-S and FCoR-AS as primers. XbaI-treated
PCR products were subcloned into XbaI-treated pFLAG-CMV2
vector. To construct pFLAG-CMV2-WT FoxO1, XbaI-treated WT-
FoxO1 fragments from pCMV5/cMyc-WT FoxO1 vector were
subcloned into XbaI-treated pFLAG-CMV2 vector. Construction of
pCMV5/cMyc-WT FoxO3a was described previously (Takaishi et al,
1999; Nakae et al, 2001). To construct pCMV5/cMyc-WT FOXO4,
human FOXO4 cDNA was ampliﬁed by PCR using PFN21AB7772
(Kazusa DNA Research Institute, Chiba, Japan) and the following
primers: 50-GGG ATCGAT (ClaI) ATGGATCCGGGGAATGAGAAT-30
(sense) and 50-GGG AAGCTT (HindIII) TCAGGGATCTGGCT
CAAAGTT-30 (antisense). After treatment with ClaI and HindIII,
PCR products were subcloned into ClaI/HindIII-treated pCMV5/
cMyc vector. All vectors produced for this study were sequenced
to conﬁrm that they had the intended sequences.
Site-directed mutagenesis
Site-directed mutagenesis was carried out using the QuickChange
RII
Site-Directed Mutagenesis Kit (Stratagene). We used the pCMV5/
cMyc-FCoR expression vector as a template. To construct S92A-
FCoR, we used the following mutagenic primers: S92A-S 50-gaa
ctcacaaagaGccacctgctgctgcct-30 and S92A-AS 50-aggcagcagcaggtgg
Ctctttgtgagttc-30. To construct T93A-FCoR, we used T93A-S 50-gaac
tcacaaagatccGcctgctgctgcct-30 and T93A-AS 50-aggcag cagcaggCgga
tctttgtgagttc-30. To construct T93D-FCoR, we used T93D-S 50-gaactc
acaaagatccGActgctgctgcct-30 and T93D-AS 50-aggcagcagcagTCggat
ctttgtgagttc-30. To construct S92A/T93D-FCoR, we used S92A/
T93A-S 50-gaactcacaaagaGccGcctgctgctgcct-30 and S92A/T93A-
AS 50-aggcagcagcaggCggCtctttgtgagttc-30. To construct I78A-FCoR,
we used I78A-S 50-ctacagagccctggctctGCtggaactctatatatcagg-30 and
I78A-AS 50-cctgatatatagagttccaGCagagccagggctctgtag-30. To con-
struct T80A-FCoR, we used T80A-S 50-ccctggctctattggagctctatatat-
caggctgg-30 and T80A-AS 50-ccagcctgatatatagagctccaatagagccaggg-
30. To construct L81A-FCoR, we used L81A-S 50-cctggctctattggaa
ctGCatatatcaggctggacttg-30 and L81A-AS50-caagtccagcctgatatatGC
agttccaatagagccagg-30. To construct L85A-FCoR, we used L85A-S
50-ggaactctatatatcaggGCggacttgaactcacaaaga-30 and L85A-AS50-
tctttgtgagttcaagtccGCcctgatatatagagttcc-30. To construct L87A-
FCoR, we used L87A-S 50-ctatatatcaggctggacGCgaactcacaa
agatccacc-30 and L87A-AS50-ggtggatctttgtgagttcGCgtccagcctgatata
tag-30.
Construction of adenoviral vectors and adenoviral
transduction
To construct an adenoviral vector encoding FCoR, we ampliﬁed the
cMyc-FCoR cDNA fragment using the pCMV5/cMyc-FCoR expres-
sion vector as a template and the following primers: 50-G GGCTAGC
(NheI) ATGGAGCAGAAGCTGATCAGC-30 (sense) and 50-GG GCTAGC
(NheI) CTAGCACATGCCTTTAGTCCC-30 (antisense). After treatment
with NheI, the PCR fragment was subcloned into NheI-treated
pShuttle2 vector (Clontech). After sequencing the vectors to
conﬁrm that they had the intended sequences, and conﬁrming
protein expression in HEK293 by transient transfection, an I-CeuI-
and PI-SceI-treated fragment was subcloned into Adeno-X viral
DNA (pAdeno-X-cMyc-FCoR) (Clontech). The adenovirus vector
was generated by transfecting HEK293 cells with the pAdeno-X-
cMyc-FCoR plasmid.
For knockdown of FCoR in 3T3-F442A cells, we used DNA-based
adenoviral vector-mediated technology (Knockout RNAi Systems;
Clontech Laboratories, Inc.), with 50-GCATGTGCTAGCATGCATA
GC-30 and 50-GCTAGCATGCATAGCCTAATG-30 as the targeted se-
quences of shRNA1 and shRNA2, respectively. The sequences of
shRNA1 and shRNA2 are 50-GATCCG GCATGTGCTAGCATGCATAGC
TTCAAGAGAGCTATGCATGCTAGCACATGC CTTTTTT TCTAGA G-30
and 50-GATCCG GCTAGCATGCATAGCCTAATG TTCAAGAGA
CATTAGGCTATGCATGCTAGC CTTTTTT TCTAGA G-30, respectively.
We selected an RNAi target sequence for FCoR using the Block-iT
RNAi Designer (Invitrogen). We used the BD Adeno-X Expression
System 1 (BD Biosciences) to generate a recombinant adenovirus
encoding FCoR-shRNA. The generation of adenovirus encoding the
cCN Foxo1 (T24A/S253A/S316A) was described previously (Nakae
et al, 2006). For induction of endogenous Igfbp1, SV40-transformed
hepatocytes were transduced with adenovirus encoding CN Foxo1
as described previously (Nakae et al, 2006). For transduction of
3T3-F442A cells with adenovirus encoding FCoR-shRNA, 3T3-
F442A cells were transduced with adenovirus as described
previously (Nakae et al, 2003).
Western blotting and fractionation of cytoplasmic and nuclear
proteins
We homogenized tissues and lysed cells in buffer containing 50mM
Tris–HCl (pH 8.0), 250mM NaCl, 1% NP-40, 0.5% deoxycholate,
0.1% SDS, and protease inhibitors (Roche Diagnostics). After
centrifugation to remove insoluble material, the proteins in 30mg
of lysate were separated using 8 or 14% SDS–PAGE, and western
blotting was performed using the indicated antibodies.
Immunoprecipitation was performed as described previously (Cao
et al, 2006). Fractionation of cytoplasmic and nuclear extracts was
performed using NE-PER extraction reagents (Pierce). Protein
concentrations in the cytoplasmic and nuclear extracts were
determined using the Micro BSA protein assay kit (Pierce), and
the proteins in aliquots (30mg) were resolved by 14% SDS–PAGE
followed by western blotting using the indicated antibody.
Detection of phosphorylated FCoR protein
For detection of phosphorylated FCoR, HEK293 cells were trans-
fected with the indicated vectors encoding cMyc-FCoR. Cells were
stimulated with forskolin (20mM) for the indicated time and har-
vested using lysis buffer containing phosphatase inhibitor as de-
scribed previously (Nakae et al, 2000). The proteins in the cell
lysates were separated by 14% SDS–PAGE and transferred onto
Immobilon-P Transfer Membrane (Millipore Corporation). After
blocking, the membrane was incubated with Phos-tag
R BTL-104
(NARD Institute Ltd.) according to manufacturer’s protocol fol-
lowed by detection with streptavidin-horseradish peroxidase con-
jugate (ECL; Amersham, Buckinghamshire, UK). The membranes
were reprobed as per manufacturer’s protocol.
In-vitro translation and glutathione S-transferase fusion
protein pull-down assay
The wild-type Fcor cDNA fragment was generated by PCR using
pCMV5/cMyc-FCoR expression vector as a template and the follow-
ing primers: 50-GG GAATTC (EcoRI) GGATGGGCGGTCCTACACGC
CGCCAT-30 (sense) and 50-GG GAATTC (EcoRI) CTAGCACATGCC
TTTAGTCCC-30 (antisense). The fragment was cloned in-frame into
the EcoRI site of pGEX-4T-2. In-vitro translation of Foxo1 and the
pull-down assay were performed as described previously (Cao et al,
2006).
In-vitro acetylation assay
GST-Foxo1-C1 fusion protein (20mg) was incubated at 301C for 1h
with 4mg of GST, GST-FCoR fusion protein, or 0.5mg of recombinant
p300 protein (ACTIVE MOTIF) and 25nCi of [
14C] acetyl-CoA
(Perkin-Elmer) in the reaction buffer (50mM Tris–HCl (pH 8.0),
100mM NaCl, 10% glycerol, 0.1mM EDTA, 1mM DTT, 1mM PMSF,
5mM sodium butyrate). Reaction products were separated by 14%
SDS–PAGE, stained with Coomassie brilliant blue, dried, exposed to
a BAS 5000 imaging plate (FujiFilm, Japan) and analysed.
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Five micrograms of GST, GST-WT FCoR, GST-T93A, GST-T93D, and
GST-RRAS as a positive control (GST-RRAS is a short sequence of
salt-inducible kinase (SIK) 2 and a substrate of PKA) were incu-
bated at 301C for 10min with 0.5 units of the catalytic subunit of
cAMP-dependent protein kinase (Promega) in the reaction buffer
(50mM Tris–HCl (pH 7.4), 0.1mM DTT, 5mM MgCl2, 0.5mM ATP).
Reaction products were separated by 14% SDS–PAGE and trans-
ferred onto a nylon membrane. Phosphorylated products were
detected using Phos-tag
R BTL-104 as described above and then
blotted with anti-GST antibody.
Generation of adipose tissue-speciﬁc FCoR transgenic mice
We cloned wild-type Fcor cDNA into the SmaI site of plasmid
pCMV5-aP2, into which the ClaI- and SmaI-treated 5.4-kb promo-
ter-enhancer fragment of the mouse aP2 gene was subcloned into
the ClaI/SmaI-treated pCMV5/cMyc vector (Nakae et al, 2008a). We
excised the transgene with ClaI and XhoI, gel-puriﬁed it and injected
it into fertilized eggs from BDF1 X C57BL/6 mice. The resulting
embryos were implanted into CD-1 foster mothers. We screened the
offspring for transgene transmission by PCR. Of 11 independent
transgenic lines obtained, 9 founders transmitted the transgene
through the germ line. We crossed each founder with C57BL/6
mice, obtained F1 mice, sacriﬁced one of the mice in each line in
which transgene was transmitted and examined transgene
expression in adipose tissues. We obtained three independent Fcor
transgenic lines (Acc. No. CDB0446T: http://www.cdb.riken.jp/arg/
TG%20mutant%20mice%20list.html) in which the transgene was
expressed in adipose tissues. Primers for genotypying are 50-ATG
G A GC A GA A GC T GA T CA G C - 3 0 and 50-CAT CCT TTC TCT GTG
ATA CTG-30.
Generation of FcorKO
The mouse genomic DNA clone containing exons 1 and 2 of the Fcor
gene was obtained from a genomic DNA library derived from the
129/Sv mouse strain. The Fcor targeting construct consisted of
5.5kb of genomic sequence that was immediately 50 of the ﬁrst
exon, followed by a 4.5-kb LacZ-cassette, a Neo-resistance gene,
and 3.5kb of genomic sequence from intron 1, exon 2, and intron 2.
The SpeI-linearized targeting vector was electroporated into TT2
embryonic stem (ES) cells (Yagi et al, 1993) as described previously.
G418-resistant clones were isolated and screened by PCR and
Southern blotting. In all, 30 out of 115 G418-resistant clones had
undergone the desired homologous recombination. Positive clones
were injected into CD-1 8-cell stage embryos, and the chimeric male
offspring was mated to C57BL/6 females. Mice carrying the
mutation in the heterozygous state were intercrossed to produce
homozygous Fcor mutants (Acc. No. CDB0612K: http://www.
cdb.riken.jp/arg/mutant%20mice%20list.html), and 20- to 24-
week-old mice were used for analysis. Primers for detection of
wild-type allele (204bp) are 50-ATGGGCGGTCCTACACGCCGC-30
and 50-CGGTGCAGTTCCCAGCCCTAC-30. Primers for detection of
knockout allele (234bp) are 50-AGCCCTTCCCCGCTGTGCACG-30
and 50-GGGTTTTCCCAGTCACGACGT-30.
Animal studies, analytical procedures, IPGTT, and ITT
We used only male mice for the following experiments, as they are
more susceptible to insulin resistance and diabetes. Animals were
fed a standard chow diet and water ad libitum in sterile cages in a
barrier animal facility with a 12-h/12-h light/dark cycle. Wild-type
littermates were used as controls. All experimental protocols using
mice were approved by the animal ethics committee of the Keio
University School of Medicine and Kobe University Graduate School
of Medicine. A HFD was started at weaning (4 weeks of age) and
continued for 20 weeks. We used the same HFD and measured the
blood glucose and insulin levels as described previously (Nakae
et al, 2008a). We carried out all assays in duplicate. Each value
represents the mean of two independent determinations. Glucose,
ITT, and CT scanning were performed as described previously
(Nakae et al, 2008a). The rectal temperature of mice was
measured using Thermal Sensor
R (Shibaura Electronics Co. Ltd).
Luciferase assay
The IGFBP-1 or G6Pase luciferase assay was performed as described
previously (Nakae et al, 2006). To construct a mouse Ppargc1a
promoter-luciferase vector, mouse genomic DNA was ampliﬁed by
PCR using the following primers: 50-GG GCTAGC (NheI)
TCATTGACTCAGGAACGACA-30 (forward primer) and 50-GG GCT
AGC (NheI) CCAGTCACATGACAAAGCTA-30 (antisense primer).
After digestion with NheI, the PCR product was subcloned into
NheI-treated pGL3-Basic vector (Promega) and sequenced to rule
out the presence of mutations. For the mouse Ppargc1a promoter
luciferase assay, HEK 293 cells were plated onto 12-well culture
dishes. Transfections were carried out on cells at a 70–80% stage of
conﬂuence using 1.5mg of pGL3/Basic-Ppargc1a reporter vector,
and/or 0.6mg of pCMV5/cMyc empty vector or pCMV5/cMyc-FCoR
expression vectors. Synthetic Renilla luciferase reporter vector
(phRL-SV40; Promega) (10ng) was used as an internal control of
transfection efﬁciency. After transfection, cells were cultured in
DMEM containing 10% fetal calf serum and incubation was
continued for 36h. After that, cells were stimulated with forskolin
(20mM) for 6h and the cells were harvested for luciferase assay.
To construct GAL4-Foxo1 expression vectors (PM-WT, -6KQ, and -
6KR FoxO1), mouse Foxo1 cDNA was ampliﬁed by PCR using the
pCMV5/cMyc-WT, -6KQ, or -6KR Foxo1 expression vectors as
templates (Kitamura et al, 2005) and the following primers: 50-GG
GGATCC (BamHI) GT ATG GCC GAG GCG CCC CAG GTG GTG-30
(sense) and 50-GG GGATCC (BamHI) TTA GCC TGA CAC CCA GCT
GTG TGT-30 (antisense). After treatment with BamHI, PCR products
were subcloned into a BamHI-treated pM vector (Clontech). To
construct GAL4-Foxo3a, the Foxo3a cDNA fragment from EcoRI/
HindII-treated PCMV5/cMyc/Foxo3a vector (Nakae et al, 2001) was
ligated into an EcoRI/HindII-treated PM vector. To construct GAL4-
FOXO4, human FOXO4 cDNA was ampliﬁed by PCR using
PFN21AB7772 (Kazusa DNA Research Institute, Chiba, Japan) and
the following primers: 50-GG GTCGAC (SalI) GCATGGATCCG
GGGAATGAGAATTCA-30 (sense) and 50-GG AAGCTT (HindIII)
TCAGGGATCTGGCTCAAAGTTGAA-30 (antisense). After treatment
with SalI and HindIII, PCR products were subcloned into the SalI/
HindIII-treated pM vector. Plasmids were sequenced to conﬁrm that
they had the intended sequences. The 5XGAL4-luciferase reporter
plasmid (pTAL-5XGAL4) was described previously (Katoh et al,
2006). For the 5XGAL4-luciferase assay, HEK293 cells were plated
onto 12-well dishes. When the cells showed 70–80% conﬂuence,
transfections were carried out using 1.5mg of pTAL-5XGAL4, 0.3mg
of several kinds of pM vector, and 0.6mg of pCMV5/cMyc empty
vector or pCMV5/cMyc-FCoR expression vectors. The synthetic
Renilla luciferase reporter vector (phRL-SV40; Promega) (10ng)
was used as an internal control for transfection efﬁciency.
For luciferase assays using the J3-tk-Luc vector, HEK 293 cells
were plated onto 12-well culture dishes. When the cells showed
70–80% conﬂuence, transfections were carried out using 0.5mgo f
the J3-tk-Luc reporter vector, 0.1mg of pcDNA3-hPPARg, 0.1mgo f
pcDNA3-hRXRa, 0.1mg of pFLAG-CNFoxo1 and/or 1.0mg
of pCMV5/cMyc empty vector or pCMV5/cMyc-FCoR expression
vectors. The synthetic Renilla luciferase reporter vector (phRL-
SV40; Promega) (10ng) was used as an internal control for trans-
fection efﬁciency. All vectors have been described previously
(Vu-Dac et al, 1995; Tachibana et al, 2005). After transfection,
cells were cultured in DMEM containing 10% fetal calf serum
and incubation was continued for 36h with 10mM of rosiglitazone
for 24h.
Chip assay
3T3-F442Acells were seeded onto 15 cm-culture dishes and induced
to differentiate into mature adipocytes as described previously
(Nakae et al, 2003). On day 4 (clonal expansion) and day 6 (end
of clonal expansion) after induction, cells were trypsinized and
ﬁxed with 1% formaldehyde for 1h at 371C. The DNA solution for
Chip PCR was prepared according to the protocol in the Chip Assay
Kit (Upstate). We performed immunoprecipitation with anti-FCoR
serum, anti-FOXO1 (H128; Santa Cruz Biotechnology, Inc.), or an
equal amount of normal rabbit IgG (Santa Cruz Biotechnology,
Inc.). We subjected the samples to PCR using the following primers:
for mouse Cdkn1a,5 0-aggaggaagactgggcatgtc-30 and 50-gagttggatcc
ctagtaaggc-30. For a Chip assay of Ppargc1a promoter, T37i cells
infected with adenovirus encoding cMyc-FCoR were ﬁxed with 1%
formaldehyde for 1h at 371C. The DNA solution for the Chip assay
was prepared as described previously (Nakae et al, 2006). We used
an anti-cMyc mouse monoclonal antibody (9E10; Santa Cruz
Biotechnology, Inc.) for immunoprecipitation of exogenous cMyc-
FCoR. We subjected the samples to PCR using the following primers
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cgctcctcatgtgatacatt-30 (antisense), and S4: 50-aatgtatcacatgagg
agcg-30 (sense) and 50-ccagtcacatgacaaagcta-30 (antisense).
Immunohistochemistry, immunoﬂuorescence, and
histological analysis
For histological analysis, we removed epididymal fat tissues from
20-week-old mice, ﬁxed the specimens in 10% paraformaldehyde,
and embedded them in parafﬁn. We mounted consecutive 10mm
sections on slides and stained them with haematoxylin and eosin.
Measurement of WATadipocyte size was performed using FLVFS-LS
software (Flovel, Tokyo) by manually tracing at least 500 adipocytes
for each genotype. Immunoﬂuorescence using SV40-transformed
hepatocytes or HEK293 cells was performed as described previously
(Nakae et al, 2006). After transduction with adenoviruses encoding
cMyc-FCoR and FLAG-3A FoxO1, cMyc-tagged FCoR was visualized
in SV40-transformed hepatocytes with anti-cMyc monoclonal
antibody and ﬂuorescein isothiocyanate-conjugated anti-mouse
IgG. FLAG-tagged CN FoxO1 was visualized with OctA-Probe (D-
8) (sc-807, Santa Cruz Biotechnology, Inc.) and a Cy3-conjugated
anti-rabbit IgG.
Statistics
We calculated descriptive statistics using ANOVA followed by
Fisher’s test (Statview; SAS Institute, Inc.). P-values of o0.05
were considered signiﬁcant.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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